Adagene's Presentation at CSCO Meeting: Adagene Inc. will present findings on its drug ADG126 at the CSCO Meeting in Jinan, China, highlighting its combination with pembrolizumab for treating advanced microsatellite stable colorectal cancer (MSS CRC).
Promising Results of ADG126: The drug has shown an objective response rate of approximately 30% and a median overall survival of 19.4 months in patients with refractory MSS CRC, while maintaining a low incidence of severe treatment-related adverse events.
ADAG
$1.82+Infinity%1D
Analyst Views on ADAG
Wall Street analysts forecast ADAG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADAG is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ADAG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADAG is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.670
Low
7.00
Averages
8.00
High
9.00
Current: 1.670
Low
7.00
Averages
8.00
High
9.00
Guggenheim
initiated
$9
2025-11-24
Reason
Guggenheim
Price Target
$9
2025-11-24
initiated
Reason
As previously reported, Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target. The company's lead product candidate muzastotug is currently in Phase 2 for patients with late-line microsatellite stable colorectal cancer without liver metastases, notes the analyst. The company has reported "compelling" Phase 1 data for muzastotug plus pembrolizumab that exceed current standard of care benchmarks in third-line and later CRC, according to the analyst, who calls this "an area of significant unmet need."
Guggenheim
initiated
$9
2025-11-24
Reason
Guggenheim
Price Target
$9
2025-11-24
initiated
Reason
Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target.
LifeSci Capital
Outperform
initiated
$8
2025-11-14
Reason
LifeSci Capital
Price Target
$8
2025-11-14
initiated
Outperform
Reason
LifeSci Capital initiated coverage of Adagene with an Outperform rating and $8 price target.
Lucid Capital
NULL
to
Buy
initiated
$9
2025-09-18
Reason
Lucid Capital
Price Target
$9
2025-09-18
initiated
NULL
to
Buy
Reason
Lucid Capital initiated coverage of Adagene with a Buy rating and $9 price target. Adagene is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based cancer immunotherapies, the analyst tells investors in a research note. The firm estimates peak sales of $1.2B by 2039 for the company's lead asset muzastotug in metastatic colorectal cancer patients with no liver metastases. Lucid sees "significant" upside in the shares if the data continue to support a potential best-in-indication profile.
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
